BCL2 and B-cell chronic lymphocytic leukemia: The predictive value of CK in CLL becomes even more relevant as the treatment of CLL is shifting drastically towards novel agents, i.e., B cell signaling kinase inhibitors and the Bcl-2 inhibitor venetoclax.